NEWS RELEASEA Submission for an Marketing Approval ofCardiovascular Patch is Filed in JapanTokyo, Japan, March 27, 2023 --- Osaka Medical and Pharmaceutical University, Fukui
Tateami Co., Ltd. and Teijin Limited announced today that the consortium has applied forapproval to market the OFT-G1 (development code) patch for cardiovascular surgery inJapan. Teijin Medical Technologies Co., Ltd., a Teijin Group company, will be
responsible for developing, manufacturing and distributing the OFT-G1.
The three parties, having established the OFT-G1's efficacy and safety by conducting
cases in Japan, will continue to improve their current technologies as well as develop aproduct pipeline strategy aimed at contributing to the treatment and quality of life ofpatients with congenital heart defects (CHD) in Japan and ultimately worldwide.
Teijin Medical Technologies has extensive experience in manufacturing and sale ofbiodegradable surgical materials with quality-control technologies. The company'sexpertise will be leveraged in order to launch and deliver the OFT-G1 to patients withcongenital heart disease as quickly as possible.

A schema of the implanted OFT-G1

Developed own native tissue over theOFT-G1 (pre-clinical study)

Thanks to medical advances in recent decades, the vast majority of pediatric patientswith heart diseases reach adulthood. A considerable number of these patients, however,
eventually require re-interventions, such as repeat surgery or catheter therapy, due toproblems with the implanted surgical materials. There still exist unsolved drawbacks ofthe existing materials, such as deterioration, calcification, and thickening with pseudointimal proliferation. Furthermore, such materials have no size adaptability to bodygrowth. As a result, hemodynamic disturbance often occurs again to be treated by there-interventions in their long life.
To solve this significant clinical problem, the three parties have devoted their efforts toresearching and developing the OFT-G1 by introducing a totally new concept. The OFTG1 is a knitted fabric consisting of bio-absorbable and non-absorbable yarns coated with

cross-linked gelatin. After implantation into the body, own native tissue grows andgradually surrounds the stretchable non-absorbable yarn while the bio-absorbable parts
disappear. The regenerated tissue has the potential to reduce the risk of inflammatory
reactions and degradation and thereby prevent the need for re-intervention.
In a clinical trial started in Japan since May 2019, no problems or reoperations due toOFT-G1 have currently occurred. As such, the OFT-G1 patch is expected to alleviate not
only physical problems but also psychological burdens due to unwanted re-interventions.
The development of the OFT-G1 has been supported by the Ministry of Economy, Tradeand Industry since 2014 as well as a program launched in 2017 by the Japan Agency for
Medical Research and Development (AMED) to facilitate collaboration between medical
academia and industry. Japan’s Ministry of Health, Labor and Welfare designated theOFT-G1 as a “SAKIGAKE” device in April 2018, providing various incentives to speed up
an approval for clinical use.
About Osaka Medical and Pharmaceutical University
Osaka Medical and Pharmaceutical University is a comprehensive institution that offers
education and research in department of medicine, pharmacy, and nursing. The
university has been providing thousands of clinical professionals by its unique curriculum.
Not only basic scientific research but also interdisciplinary research activities areconducted to solve unmet medical needs. Of note, various medical devices have been
invented there by active industry-academia-government collaborations.
The University Hospital provides various advanced medical treatments, such as thestate-of-the arts cancer therapy including boron neutron capture therapy, robot surgery,and genomics medicine.
URL: https://www.ompu.ac.jp/
Press Contact
Section of Promoting Academia-Industry-Government Cooperation
Center for Medical Research & Development
Osaka Medical and Pharmaceutical University+81 72 684 7141
sangakukan@ompu.ac.jp
About Fukui Tateami Co., Ltd.
Fukui Tateami, with 78 years of experience and advanced technology, has become oneof Japan's largest manufacturers of warp-knitted fabric with a wide spectrum ofapplications, including fashionwear, sportswear, automotive interiors, and industrial
materials. After equipped with fully clean room in 2017, the company expanded its
business field into the medical textiles to solve medical unmet needs. Fukui Tateami is
the first textile company which obtained ISO13485 certification in Japan. Fukui Tateami
posted sales of JPY2.8 billion (USD 26 million) and total assets of JPY 2.6 billion (USD23 million) in the fiscal year ending on March 31, 2022.
Please visit http://www.fukutate.co.jp/enPress ContactGeneral Affairs
Fukui Tateami Co., Ltd.
+81 776 54 3602
info@fukutate.co.jp
About the Teijin GroupTeijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions”, Teijin aims to be a company thatsupports the society of the future. The group comprises some 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2022.
Press Contact
Investor and Public Relations Department
Teijin Limited
pr@teijin.co.jp